The Lundberg Laboratory for Diabetes Research, Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Int J Obes (Lond). 2021 May;45(5):934-943. doi: 10.1038/s41366-021-00757-x. Epub 2021 Jan 28.
Cell senescence is defined as a state of irreversible cell cycle arrest combined with DNA damage and the induction of a senescence-associated secretory phenotype (SASP). This includes increased secretion of many inflammatory agents, proteases, miRNA's, and others. Cell senescence has been widely studied in oncogenesis and has generally been considered to be protective, due to cell cycle arrest and the inhibition of proliferation. Cell senescence is also associated with ageing and extensive experimental data support its role in generating the ageing-associated phenotype. Senescent cells can also influence proximal "healthy" cells through SASPs and, e.g., inhibit normal development of progenitor/stem cells, thereby preventing tissue replacement of dying cells and reducing organ functions. Recent evidence demonstrates that SASPs may also play important roles in several chronic diseases including diabetes and cardiovascular disease. White adipose tissue (WAT) cells are highly susceptible to becoming senescent both with ageing but also with obesity and type 2 diabetes, independently of chronological age. WAT senescence is associated with inappropriate expansion (hypertrophy) of adipocytes, insulin resistance, and dyslipidemia. Major efforts have been made to identify approaches to delete senescent cells including the use of "senolytic" compounds. The most established senolytic treatment to date is the combination of dasatinib, an antagonist of the SRC family of kinases, and the antioxidant quercetin. This combination reduces cell senescence and improves chronic disorders in experimental animal models. Although only small and short-term studies have been performed in man, no severe adverse effects have been reported. Hopefully, these or other senolytic agents may provide novel ways to prevent and treat different chronic diseases in man. Here we review the current knowledge on cellular senescence in both murine and human studies. We also discuss the pathophysiological role of this process and the potential therapeutic relevance of targeting senescence selectively in WAT.
细胞衰老被定义为一种不可逆的细胞周期停滞状态,伴有 DNA 损伤和衰老相关分泌表型 (SASP) 的诱导。这包括增加许多炎症因子、蛋白酶、miRNA 等的分泌。细胞衰老在肿瘤发生学中得到了广泛的研究,由于细胞周期停滞和增殖抑制,通常被认为是保护性的。细胞衰老也与衰老有关,大量实验数据支持其在产生与衰老相关表型中的作用。衰老细胞还可以通过 SASP 影响邻近的“健康”细胞,例如,抑制祖细胞/干细胞的正常发育,从而防止死亡细胞的组织替代,降低器官功能。最近的证据表明,SASP 也可能在包括糖尿病和心血管疾病在内的几种慢性疾病中发挥重要作用。白色脂肪组织 (WAT) 细胞很容易衰老,无论是随着年龄的增长还是肥胖和 2 型糖尿病,与实际年龄无关。WAT 衰老与脂肪细胞的不适当扩张(肥大)、胰岛素抵抗和血脂异常有关。人们已经做出了巨大的努力来识别清除衰老细胞的方法,包括使用“衰老细胞清除剂”化合物。迄今为止,最成熟的衰老细胞清除治疗方法是 dasatinib(Src 家族激酶的拮抗剂)和抗氧化剂槲皮素的联合使用。这种组合可减少细胞衰老并改善实验动物模型中的慢性疾病。尽管在人类中只进行了小规模和短期的研究,但尚未报告严重的不良反应。希望这些或其他衰老细胞清除剂可以为预防和治疗人类的不同慢性疾病提供新的方法。在这里,我们回顾了在小鼠和人类研究中关于细胞衰老的现有知识。我们还讨论了这个过程的病理生理学作用,以及选择性靶向 WAT 衰老的潜在治疗相关性。